Drug Trial Radar · NCT02834013
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Last checked: Nov 19, 2026Latest source record: Jun 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
798
Actual
Start
Jan 30, 2017
Primary completion
May 1, 2026
Study completion Jun 1, 2027
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- First posted
- Jul 15, 2016
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase II trial studies nivolumab and ipilimumab in treating patients with rare tumors. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial enrolls participants for the following cohorts based on condition: 1. Epithelial tumors of nasal cavity, sinuses, nasopharynx: A) Squamous cell carcinoma with variants of nasal cavity, sinuses, and nasopharynx and trachea (excluding laryngeal, nasopharyngeal cancer \[NPC\], and squamous cell carcinoma of the head and neck \[SCCHN\]) B) Adenocarcinoma and variants of nasal cavity, sinuses, and nasopharynx (closed to accrual 07/27/2018) 2. Epithelial tumors of major salivary glands (closed to accrual 03/20/2018) 3. Salivary gland type tumors of head and neck, lip, esophagus, stomach, trachea and lung, breast and other location (closed to accrual) 4. Undifferentiated carcinoma of gastrointestinal (GI) tract 5. Adenocarcinoma with variants of small intestine (closed to accrual 05/10/2018) 6. Squamous cell carcinoma with variants of GI tract (stomach small intestine, colon, rectum, pancreas) (closed to accrual 10/17/2018) 7. Fibromixoma and low grade mucinous adenocarcinoma (pseudomixoma peritonei) of the appendix and ovary (closed to accrual 03/20/2018) 8. Rare pancreatic tumors including acinar cell carcinoma, mucinous cystadenocarcinoma or serous cystadenocarcinoma. Pancreatic adenocarcinoma is not eligible (closed to accrual) 9. Intrahepatic cholangiocarcinoma (closed to accrual 03/20/2018) 10. Extrahepatic cholangiocarcinoma and bile duct tumors (closed to accrual 03/20/2018) 11. Sarcomatoid carcinoma of lung 12. Bronchoalveolar carcinoma lung. This condition is now also referred to as adenocarcinoma in situ, minimally invasive adenocarcinoma, lepidic predominant adenocarcinoma, or invasive mucinous adenocarcinoma 13. Non-epithelial tumors of the ovary: A) Germ cell tumor of ovary B) Mullerian mixed tumor and adenosarcoma (closed to accrual 03/30/2018) 14. Trophoblastic tumor: A) Choriocarcinoma (closed to accrual) 15. Transitional cell carcinoma other than that of the renal, pelvis, ureter, or bladder (closed to accrual) 16. Cell tumor of the testes and extragonadal germ tumors: A) Seminoma and testicular sex cord cancer B) Non seminomatous tumor C) Teratoma with malignant transformation (closed to accrual) 17. Epithelial tumors of penis - squamous adenocarcinoma cell carcinoma with variants of penis (closed to accrual) 18. Squamous cell carcinoma variants of the genitourinary (GU) system 19. Spindle cell carcinoma of kidney, pelvis, ureter 20. Adenocarcinoma with variants of GU system (excluding prostate cancer) (closed to accrual 07/27/2018) 21. Odontogenic malignant tumors 22. Pancreatic neuroendocrine tumor (PNET) (formerly named: Endocrine carcinoma of pancreas and digestive tract.) (closed to accrual) 23. Neuroendocrine carcinoma including carcinoid of the lung (closed to accrual 12/19/2017) 24. Pheochromocytoma, malignant (closed to accrual) 25. Paraganglioma (closed to accrual 11/29/2018) 26. Carcinomas of pituitary gland, thyroid gland parathyroid gland and adrenal cortex (closed to accrual) 27. Desmoid tumors 28. Peripheral nerve sheath tumors and NF1-related tumors (closed to accrual 09/19/2018) 29. Malignant giant cell tumors 30. Chordoma (closed to accrual 11/29/2018) 31. Adrenal cortical tumors (closed to accrual 06/27/2018) 32. Tumor of unknown primary (Cancer of Unknown Primary; CuP) (closed to accrual 12/22/2017) 33. Not Otherwise Categorized (NOC) Rare Tumors \[To obtain permission to enroll in the NOC cohort, contact: S1609SC@swog.org\] (closed to accrual 03/15/2019) 34. Adenoid cystic carcinoma (closed to accrual 02/06/2018) 35. Vulvar cancer (closed to accrual) 36. MetaPLASTIC carcinoma (of the breast) (closed to accrual) 37. Gastrointestinal stromal tumor (GIST) (closed to accrual 09/26/2018) 38. Perivascular epithelioid cell tumor (PEComa) 39. Apocrine tumors/extramammary Paget's disease (closed to accrual) 40. Peritoneal mesothelioma 41. Basal cell carcinoma (temporarily closed to accrual 04/29/2020) 42. Clear cell cervical cancer 43. Esthenioneuroblastoma (closed to accrual) 44. Endometrial carcinosarcoma (malignant mixed Mullerian tumors) (closed to accrual) 45. Clear cell endometrial cancer 46. Clear cell ovarian cancer (closed to accrual) 47. Gestational trophoblastic disease (GTD) 48. Gallbladder cancer 49. Small cell carcinoma of the ovary, hypercalcemic type 50. PD-L1 amplified tumors 51. Angiosarcoma 52. High-grade neuroendocrine carcinoma (pancreatic neuroendocrine tumor \[PNET\] should be enrolled in Cohort 22; prostatic neuroendocrine carcinomas should be enrolled into Cohort 53). Small cell lung cancer is not eligible (closed to accrual) 53. Treatment-emergent small-cell neuroendocrine prostate cancer (t-SCNC)
Conditions
- Acinar Cell Carcinoma
- Adenoid Cystic Carcinoma
- Adrenal Cortical Carcinoma
- Adrenal Gland Pheochromocytoma
- Anal Canal Neuroendocrine Carcinoma
- Anal Canal Undifferentiated Carcinoma
- Angiosarcoma
- Apocrine Neoplasm
- Appendix Mucinous Adenocarcinoma
- Bartholin Gland Transitional Cell Carcinoma
- Basal Cell Carcinoma
- Bladder Adenocarcinoma
- Breast Metaplastic Carcinoma
- Cervical Adenocarcinoma
- Cholangiocarcinoma
- Chordoma
- Colorectal Squamous Cell Carcinoma
- Desmoid Fibromatosis
- Endometrial Transitional Cell Carcinoma
- Endometrioid Adenocarcinoma
- Esophageal Neuroendocrine Carcinoma
- Esophageal Undifferentiated Carcinoma
- Extrahepatic Bile Duct Carcinoma
- Extramammary Paget Disease
- Fallopian Tube Adenocarcinoma
- Fallopian Tube Transitional Cell Carcinoma
- Fibromyxoid Tumor
- Gallbladder Carcinoma
- Gastric Neuroendocrine Carcinoma
- Gastric Squamous Cell Carcinoma
- Gastric Undifferentiated Carcinoma
- Gastrointestinal Stromal Tumor
- Gestational Trophoblastic Tumor
- Giant Cell Carcinoma
- Human Papillomavirus-Independent Cervical Adenocarcinoma, Clear Cell-Type
- Intestinal Neuroendocrine Carcinoma
- Intrahepatic Cholangiocarcinoma
- Lung Neuroendocrine Tumor
- Lung Sarcomatoid Carcinoma
- Major Salivary Gland Carcinoma
- Malignant Neoplasm of Unknown Primary
- Malignant Odontogenic Neoplasm
- Malignant Peripheral Nerve Sheath Tumor
- Malignant Solid Neoplasm
- Malignant Testicular Sex Cord-Stromal Tumor
- Metastatic Pituitary Neuroendocrine Tumor
- Minimally Invasive Lung Adenocarcinoma
- Mixed Mesodermal (Mullerian) Tumor
- Mucinous Adenocarcinoma
- Mucinous Cystadenocarcinoma
- Nasal Cavity Adenocarcinoma
- Nasal Cavity Carcinoma
- Nasopharyngeal Carcinoma
- Nasopharyngeal Low Grade Papillary Adenocarcinoma
- Nasopharyngeal Undifferentiated Carcinoma
- Oral Cavity Carcinoma
- Oropharyngeal Undifferentiated Carcinoma
- Ovarian Adenocarcinoma
- Ovarian Germ Cell Tumor
- Ovarian Mucinous Adenocarcinoma
- Ovarian Squamous Cell Carcinoma
- Ovarian Transitional Cell Carcinoma
- Pancreatic Acinar Cell Carcinoma
- Pancreatic Neuroendocrine Carcinoma
- Paraganglioma
- Paranasal Sinus Adenocarcinoma
- Paranasal Sinus Carcinoma
- Parathyroid Gland Carcinoma
- PEComa
- Penile Squamous Cell Carcinoma
- Peritoneal Mesothelial Neoplasm
- Placental Choriocarcinoma
- Primary Peritoneal High Grade Serous Adenocarcinoma
- Pseudomyxoma Peritonei
- Rare Disorder
- Scrotal Squamous Cell Carcinoma
- Seminal Vesicle Adenocarcinoma
- Seminoma
- Serous Cystadenocarcinoma
- Small Intestinal Adenocarcinoma
- Small Intestinal Squamous Cell Carcinoma
- Spindle Cell Neoplasm
- Teratoma With Somatic-Type Malignancy
- Testicular Non-Seminomatous Germ Cell Tumor
- Thyroid Gland Carcinoma
- Tracheal Carcinoma
- Transitional Cell Carcinoma
- Ureter Adenocarcinoma
- Ureter Squamous Cell Carcinoma
- Urethral Adenocarcinoma
- Urethral Squamous Cell Carcinoma
- Vaginal Adenocarcinoma
- Vaginal Squamous Cell Carcinoma, Not Otherwise Specified
- Vulvar Carcinoma
Interventions
Biospecimen CollectionProcedure
Undergo blood sample collection
Computed TomographyProcedure
Undergo CT
Echocardiography TestProcedure
Undergo ECHO
IpilimumabBiological
Given IV
Magnetic Resonance ImagingProcedure
Undergo MRI
NivolumabBiological
Given IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall response rate (ORR)Time frame: Up to 10 years
Locations
1,007 sites in 2 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham Cancer Center
Birmingham, Alabama
University of South Alabama Mitchell Cancer Institute
Mobile, Alabama
Anchorage Associates in Radiation Medicine
Anchorage, Alaska
Anchorage Radiation Therapy Center
Anchorage, Alaska
Alaska Breast Care and Surgery LLC
Anchorage, Alaska
Alaska Oncology and Hematology LLC
Anchorage, Alaska
Alaska Women's Cancer Care
Anchorage, Alaska
Anchorage Oncology Centre
Anchorage, Alaska
Katmai Oncology Group
Anchorage, Alaska
Providence Alaska Medical Center
Anchorage, Alaska
Fairbanks Memorial Hospital
Fairbanks, Alaska
CTCA at Western Regional Medical Center
Goodyear, Arizona
Kingman Regional Medical Center
Kingman, Arizona
Cancer Center at Saint Joseph's
Phoenix, Arizona
Highlands Oncology Group - Fayetteville
Fayetteville, Arkansas
Mercy Hospital Fort Smith
Fort Smith, Arkansas
CHI Saint Vincent Cancer Center Hot Springs
Hot Springs, Arkansas
NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro
Jonesboro, Arkansas
University of Arkansas for Medical Sciences
Little Rock, Arkansas
Highlands Oncology Group - Rogers
Rogers, Arkansas
Highlands Oncology Group
Springdale, Arkansas
Kaiser Permanente-Anaheim
Anaheim, California
Kaiser Permanente-Deer Valley Medical Center
Antioch, California
Mission Hope Medical Oncology - Arroyo Grande
Arroyo Grande, California
PCR Oncology
Arroyo Grande, California
Sutter Auburn Faith Hospital
Auburn, California
Sutter Cancer Centers Radiation Oncology Services-Auburn
Auburn, California
AIS Cancer Center at San Joaquin Community Hospital
Bakersfield, California
Kaiser Permanente-Baldwin Park
Baldwin Park, California
Kaiser Permanente-Bellflower
Bellflower, California
Alta Bates Summit Medical Center-Herrick Campus
Berkeley, California
Keck Medicine of USC Buena Park
Buena Park, California
Providence Saint Joseph Medical Center/Disney Family Cancer Center
Burbank, California
Mills-Peninsula Medical Center
Burlingame, California
Sutter Cancer Centers Radiation Oncology Services-Cameron Park
Cameron Park, California
Mercy Cancer Center - Carmichael
Carmichael, California
Mercy San Juan Medical Center
Carmichael, California
Eden Hospital Medical Center
Castro Valley, California
UC Irvine Health Cancer Center-Newport
Costa Mesa, California
Sutter Davis Hospital
Davis, California
Showing 40 of 1,007 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.